R-DA-EPOCH in Aggressive CD 20 Positive B Cell Lymphomas: Real-World Experience

Dose adjusted EPOCH with rituximab (R-DA-EPOCH) has shown improved survival in clinical trials Burkitt ’s lymphoma (BL) and Primary mediastinal B cell lymphoma (PMBCL).

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Prasanth Ganesan, Harshvardhan Atreya, Venkatraman Radhakrishnan, Manikandan Dhanushkodi, Thanda Joshua, Krishnarathinam Kannan, Shirley Sundersingh, Triavdi Ganesan, Tenali Sagar Source Type: research